Entyce is a drug owned by ELANCO US INC. It is protected by 3 US drug patents filed from 2022 to 2036. Out of these, 2 patents are active and 1 patent has expired. Details of Entyce’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US6673929 | 13 Jun, 2022 | Expired |
Exclusivity Information
Entyce holds 1 exclusivity out of which 1 has expired. Details of Entyce's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | May 16, 2021 |
About Entyce
Entyce is a drug
owned by ELANCO US INC.
Entyce uses
Capromorelin as the active
ingredient.
Active Ingredient:
Entyce uses
Capromorelin as the active ingredient.
Check out other Drugs and Companies using
Capromorelin ingredient.